Form 4: Prelude Therapeutics Executive Granted Stock Options

Bryant David Lim, CLO, CFO, and Corporate Secretary of Prelude Therapeutics, was granted stock options for 200,000 shares on February 4, 2025.

Summary

• Bryant David Lim, the CLO, CFO, and Corporate Secretary of Prelude Therapeutics Inc., was granted employee stock options on February 4, 2025.
• The options grant covers 200,000 shares of common stock.
• The exercise price of the options is $1.11 per share.
• The options vest over time, with 25% vesting on February 4, 2026, and the remainder vesting monthly over the subsequent 36 months, contingent upon continued service to the company.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the executive's role and the company's future.

Positives

• The granting of stock options to a key executive like Bryant David Lim can be seen as a positive incentive for him to remain with the company and contribute to its success.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The terms of the grant, such as the vesting schedule and exercise price, are typically aligned with the company's long-term performance goals.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their executives.
• The vesting schedule of 25% after one year followed by monthly vesting is a fairly typical arrangement.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive company growth.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, Prelude Therapeutics, Bryant David Lim, executive compensation, Form 4, PRLD, vesting